Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.

Papi A. et al, (2024), Respiratory medicine, 224

Dupilumab reduces exacerbations independent of changes in biomarkers in moderate-to-severe asthma.

Pavord ID. et al, (2024), The journal of allergy and clinical immunology. In practice

Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical Trials.

van Dijkman SC. et al, (2024), Advances in therapy, 41, 1201 - 1225

The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.

Russell RJ. et al, (2024), The European respiratory journal

Type-2 inflammation: a key treatable trait associated with lung function decline in chronic airways disease

Petousi N. et al, (2024), Thorax

Anti-inflammatory effects of oral prednisolone at stable state in people treated with mepolizumab: a proteomic and bulk transcriptomics analysis

Howell I. et al, (2024)

Baseline characteristics and ICS/LAMA/LABA response in asthma: analyses from the CAPTAIN study.

Boulet L-P. et al, (2024), J Allergy Clin Immunol Pract

Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma.

Pavord ID. et al, (2024), American journal of respiratory and critical care medicine

Pioneering a paradigm shift in asthma management: remission as a treatment goal.

Lommatzsch M. et al, (2024), The Lancet. Respiratory medicine, 12, 96 - 99

Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19

Luo J. et al, (2024)

Phenotyping of Severe Asthma in the Era of Broad-acting Anti-asthma Biologics.

Bourdin A. et al, (2024), J Allergy Clin Immunol Pract

Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.

Bacharier LB. et al, (2024), The Journal of allergy and clinical immunology

From treatable traits to GETomics in airway disease: moving towards clinical practice.

Papi A. et al, (2024), European respiratory review : an official journal of the European Respiratory Society, 33

How have we measured trial outcomes of asthma attack treatment? A systematic review.

Howell I. et al, (2024), ERJ open research, 10, 660 - 2023

Impact of sex on severe asthma: a cross-sectional retrospective analysis of UK primary and specialist care.

Loewenthal L. et al, (2023), Thorax

New statement and new hope for patients with refractory chronic cough.

Pavord I., (2023), Thorax, 78, s1 - s2

Fractional exhaled nitric oxide (FeNO): the future of asthma care?

Wang K. et al, (2023), The British journal of general practice : the journal of the Royal College of General Practitioners, 73, 565 - 568

Tezepelumab in patients with allergic and eosinophilic asthma.

Caminati M. et al, (2023), Allergy

Understanding the Clinical Implications of Individual Patient Characteristics and Treatment Choice on the Risk of Exacerbation in Asthma Patients with Moderate-Severe Symptoms.

Singh D. et al, (2023), Advances in therapy, 40, 4606 - 4625

Which biologic? New findings from a real‐world study

Lavoie G. and Pavord ID., (2023), Respirology

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?